Key facts
- This page summarizes Rabia Gurses Ozden's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2025, 16:05.
Rabia Gurses Ozden - 25 Feb 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ADVM
- Reported as of
- 25 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2025, 16:05:13 UTC
- Prior SEC filing
- 06 Aug 2024
- Next SEC filing
- 20 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aneta Fergson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Rabia Gurses Ozden filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 27 Feb 2025.
Change
- Previous filing in this sequence was filed on 06 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADVM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,125
- Change %
- Price
- $0.000000
- Shares after
- 8,125
- Date
- 25 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADVM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +48,750
- Change %
- Price
- $0.000000
- Shares after
- 48,750
- Date
- 25 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,750
- Exercise price
- $4.20
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of Common Stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-third (1/3rd) of the total number of shares subject to this award on each anniversary of March 1, 2025 (the "Vesting Commencement Date"), so that all of the shares subject to the RSUs are vested on the third (3rd) annual anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each vesting date.
Footnote F2
Twenty-five percent (25%) of the total number shares subject to the Option shall vest and become exercisable one year after the Vesting Commencement Date, and one-forty-eighth (1/48th) of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, so that all of the shares subject to the Option are vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each vesting date.